Looking for the latest unitedhealth group stock statistics? This data-driven breakdown covers everything from revenue growth and profit margins to EPS trends and stock performance, helping you quickly understand how UnitedHealth Group is really performing beneath the surface—and what that means for investors and traders heading into 2026.
Despite generating over $447 billion in annual revenue, UnitedHealth Group has been declining profits and margin pressure—a disconnect that’s catching many investors off guard.
On the surface, UNH looks like a dominant, defensive giant—massive scale, consistent growth, and deep exposure to long-term healthcare demand. But under the hood, the story is shifting.
Rising medical costs, tighter reimbursement rates, and operational headwinds are starting to squeeze profitability in a business that already runs on thin margins.
That’s where the real opportunity—and risk—comes in.
For traders and investors, UNH is no longer just a slow-moving blue chip. It’s becoming increasingly sensitive to earnings surprises, guidance changes, and policy developments, which can trigger sharp, momentum-driven moves.
In this deep dive into unitedhealth group stock statistics, we break down the key data points that matter most—from revenue and earnings trends to margins and stock performance—so you can see exactly where the strength is, where the cracks are forming, and how to approach the stock going forward.
Key UnitedHealth (UNH) Statistics
UnitedHealth Group remains one of the largest and most influential companies in the market—but the numbers tell a more nuanced story beneath the surface:
- Revenue (2025): $447.6 billion (+12% YoY)
- Net Income (2025): ~$12.1 billion (↓ significantly YoY from ~$22B in 2023)
- Operating Income: ~$19.0 billion
- Net Margin: ~2.7% (near cycle lows)
- EPS (TTM): ~$13.28 (down sharply from ~$24 in 2023)
- Return on Equity (ROE): ~17.5%
- Market Cap: ~$313 billion
- P/E Ratio: ~17.8
- Dividend Yield: ~2.6% – 3.1% range depending on price fluctuations Annual Dividend:$8.84 per share, paid quarterly (~$2.21 per quarter) Dividend Yield vs Investment: About $2.80–$3.10 annually for every $100 invested
- Revenue is at all-time highs, but earnings and margins are compressing
- EPS has been cut nearly in half in ~2 years
- Profitability is currently (2026) sitting near the low end of its historical range
👉 Trader Insight: UNH is a massive revenue machine, but operates on razor-thin margins—which is exactly why earnings misses hit the stock so hard.
UNH Revenue Growth Statistics
UnitedHealth Group has delivered massive top-line expansion, with revenue nearly doubling from roughly $200 billion in 2017 to about $447 billion in 2025, marking another record year despite growing operational pressures.
This kind of growth is driven by pure scale—continued Medicare Advantage expansion, the rapid rise of Optum’s healthcare services and data ecosystem, and a steady strategy of acquisitions and vertical integration.
But here’s the catch: this is volume-driven growth, not margin-driven growth. UnitedHealth is adding revenue faster than it’s improving profitability, which means the business is becoming larger—but not necessarily more efficient. That distinction matters.
It’s why the stock increasingly reacts less to revenue beats and more to cost trends, margins, and forward guidance. In other words, for UNH, revenue growth alone isn’t the bullish signal it used to be.
UNH Profitability & Margin Compression
UnitedHealth Group has seen a sharp deterioration in profitability, with net income falling from roughly $22.4 billion in 2023 to around $12 billion in 2025, while net margins have compressed to about 2.7%—near the lower end of its historical 2.7% to 6.2% range over the past decade.
Despite massive revenue growth, this highlights a key reality: UNH operates as a low-margin, high-volume business, where even small increases in medical costs or operational expenses can significantly impact earnings.
The graph above shows long-term stability and the recent breakdown. You can clearly see margin compression across all levels, which reinforces the “revenue up, profitability down” thesis.
For traders, this is where things get interesting. When margins are this tight, earnings become extremely sensitive to cost changes and guidance shifts, which can trigger outsized moves in the stock.
That’s why UNH is increasingly behaving less like a slow, defensive name and more like a catalyst-driven trade around earnings, where margin commentary—not revenue—is often the real driver of momentum.
UNH Earnings & EPS Trends
UnitedHealth Group has seen earnings steadily trend lower, with EPS falling from about $24.12 in 2023 to $15.64 in 2024, and down again to roughly $13.28 in 2025.
Rather than a one-off drop, this points to a sustained downtrend in earnings power, even as the business continues to grow on the surface.
In fact, over the past 3 years, UNH has seen consistently shrinking EPS:
- 2024 annual EPS was $15.51, a 35% decline from 2023.
- 2025 annual EPS was $13.23, a 14.7% decline from 2024.
- EPS for the twelve months ending December 31, 2025 was $13.19, a 14.96% decline year-over-year. UnitedHealth Group
- EPS for the quarter ending December 31, 2025 was $0.01, a 99.83% decline year-over-year.
The pressure is coming from multiple angles—higher medical costs, tighter Medicare reimbursement rates, and non-recurring hits like cyber-related disruptions and restructuring efforts.
These aren’t isolated issues; they reflect a broader shift in the cost structure of the business that’s weighing on results.
👉 Trader insight: For traders, the key takeaway is simple: UNH is now more about expectations vs reality than raw growth. With earnings already trending lower, the stock tends to react sharply to any signal that this decline is either stabilizing—or getting worse.
UNH Efficiency & Returns
UnitedHealth Group continues to generate solid returns despite mounting margin pressure, with return on equity (ROE) around 17.5% and return on assets (ROA) near 5.4%.
These figures suggest the company is still operating efficiently relative to its size, especially for a business with such massive scale and thin margins. What this tells investors is that, even as profitability tightens, UNH hasn’t lost its ability to generate returns on capital.
That’s a key reason why the stock continues to hold up better than many peers and why analysts still view it as a fundamentally strong operator.
For long-term investors, it signals that the core business remains intact—while for traders, it helps explain why downside moves are often met with support, particularly if there are signs of stabilization in margins or earnings.
UNH Market Segment & Business Model Insight
UnitedHealth Group operates through two primary segments that together drive its massive scale and evolving growth profile.
The UnitedHealthcare division—its insurance arm—remains the largest revenue contributor, with Medicare Advantage serving as a key driver of growth.
However, this segment is also highly sensitive to government reimbursement rates and regulatory changes, which makes it more exposed to the margin pressures currently impacting the industry.
On the other side, Optum—which includes healthcare services, pharmacy, and data-driven care delivery—has become an increasingly important piece of the business.
While smaller in relative revenue contribution, it offers higher long-term margin potential and positions UNH deeper into the healthcare value chain through vertical integration.
👉 Trader insight: UnitedHealthcare generates the bulk of the cash flow, but Optum is where much of the future growth and margin expansion potential lies. For investors and traders, that dynamic matters—because shifts in performance or guidance from either segment can have very different implications for the stock.
UNH Stock Performance Stats
UnitedHealth Group has seen a notable shift in stock performance, declining roughly 30% over the past 12 months and sitting around -2% year-to-date, reflecting growing investor concern around margins and earnings trends.
Despite being traditionally viewed as a stable, defensive healthcare name, the stock is now showing increased sensitivity to earnings outcomes, with analysts expecting ~6% moves following earnings reports.
For traders, this marks a clear change in behavior. UNH is no longer trading like a slow-moving blue chip—instead, it’s becoming more volatile and reactive to catalysts, particularly around earnings, guidance, and cost commentary.
That shift opens the door for more short-term trading opportunities, as the stock increasingly responds to sentiment and expectations rather than just long-term fundamentals.
Dividend History & Yield
UnitedHealth Group has built a strong reputation as a consistent dividend growth stock, even if it’s not typically viewed as a high-yield name.
The company began paying dividends in 1990 and transitioned to quarterly payouts in 2010, steadily increasing its distribution ever since.
Today, UNH pays an annual dividend of roughly $8.84 per share, with a yield in the ~2.7%–3.1% range, depending on market conditions.
While that yield isn’t exceptionally high, the real story is growth—UnitedHealth has increased its dividend for 16–17 consecutive years, with a 5-year growth rate of ~12%+ annually.
Looking at the trend, dividends have climbed significantly over time—from about $2.87 per share in 2017 to over $8.70+ in 2025, reflecting consistent capital returns alongside business expansion.
This kind of steady increase places UNH more in the category of a “dividend growth compounder” rather than a traditional income stock.
👉 Trader insight: UNH’s dividend isn’t about yield—it’s about reliable, compounding income growth backed by strong cash flow. But with margins tightening and earnings under pressure, the key question going forward is whether that double-digit dividend growth can continue at the same pace.
UNH Key Investment Risks
UnitedHealth Group faces several important risks that are directly impacting both its profitability and stock performance:
- Rising Medical Costs: The biggest driver of margin compression right now. As healthcare utilization increases—especially among Medicare populations—UNH is paying out more in claims, which eats directly into already thin margins.
- Medicare Advantage Regulatory Pressure: A large portion of UNH’s revenue comes from government-backed plans. Changes to reimbursement rates, stricter regulations, or lower payment growth can significantly impact earnings and future guidance.
- DOJ Investigations & Political Risk: Ongoing regulatory scrutiny and potential legal challenges introduce uncertainty. Healthcare is a highly politicized industry, and policy changes can quickly shift the landscape.
- Declining Profitability Despite Growth: While revenue continues to climb, earnings and margins are trending lower. This disconnect raises concerns about the sustainability of growth and whether the business can regain operating leverage.
👉 Trader insight: UNH’s biggest risks aren’t about demand—they’re about cost control, regulation, and margins, which is exactly why the stock has become more sensitive to earnings and forward guidance.
UNH Key Investment Advantages
UnitedHealth Group still has several powerful strengths that help explain why it remains a core holding for many long-term investors:
- Massive Scale & Market Leadership: With over $447B in annual revenue, UNH is one of the largest healthcare companies in the world, giving it strong negotiating power and competitive advantages across insurance and care delivery.
- Diversified Business Model: The combination of UnitedHealthcare (insurance) and Optum (services, pharmacy, data) creates multiple revenue streams and reduces reliance on any single segment.
- Strong Cash Flow Generation: Even with margin pressure, the business generates significant cash, supporting share buybacks, dividends, and reinvestment into growth.
- High Returns on Capital: With ROE ~17.5%, UNH continues to demonstrate efficient capital allocation relative to peers.
- Long-Term Healthcare Demand Tailwinds: Aging populations, increased healthcare utilization, and Medicare expansion provide a structural growth backdrop.
- Optum Growth Opportunity: The Optum segment offers higher-margin, long-term upside, positioning UNH beyond traditional insurance into a more integrated healthcare platform.
👉Trader insight: Despite near-term margin pressure, UNH still combines scale, diversification, and long-term demand tailwinds—which is why it continues to attract institutional and long-term investor interest.
UNH Competitors & Industry Trends
What you’re seeing with UNH isn’t isolated at all. It’s actually an industry-wide shift, and some of the best comparable names are dealing with the exact same structural pressures.
Here are a few other competitors that have been experiencing similar issues.
Centene Corporation (CNC)
Centene is probably the closest comp to UNH from a margin perspective—and it’s getting hit hard.
- Reported over $1B in losses in Q4 2025
- Seeing declining Medicare enrollment and pressure in ACA markets
What’s happening:
Centene is heavily exposed to government-backed plans (Medicare + Medicaid)—the exact areas where:
- reimbursement rates are tightening
- utilization (costs) is rising
Same playbook as UNH → rising costs > revenue growth
Oscar Health (OSCR)
Oscar is like the extreme version of this problem.
- $443M net loss in 2025 despite strong growth
- Revenue up ~27% YoY, but losses widened significantly
- Medical loss ratio jumped to 87.4%+
The key stat here: They’re spending ~87 cents of every $1 on medical costs. Same pattern as UNH:
- Growing fast
- But costs rising even faster
Humana (HUM)
Humana is another major Medicare-heavy player—and it’s feeling it too.
- Medical cost ratio around ~91%
- Losing members and cutting unprofitable plans
- Stock has been volatile due to margin recovery concerns
Key issue: They’ve had to reprice plans and cut benefits just to stabilize margins
CVS Health (CVS)
CVS is interesting because it shows the same problem at massive scale:
- $402B+ revenue (record)
- But operating income dropped ~45%
Sound familiar? It’s the exact same story as UNH… Big revenue growth with profits collapsing.
Elevance Health (ELV)
- Declining Medicare Advantage enrollment
- Facing pressure from reimbursement + cost trends
👉 Trader insight: This isn’t a company-specific issue—it’s a structural reset across the entire health insurance industry. Across the board, insurers are dealing with rising medical utilization (post-COVID demand surge), higher drug and care costs, tighter government reimbursement (Medicare Advantage) and regulatory scrutiny. The result: Margins are getting squeezed everywhere
UnitedHealth Group Stock Statistics – Trader Takeaways
UnitedHealth Group is not a traditional momentum growth stock—it’s a margin-sensitive giant, and that distinction matters.
Despite generating over $447 billion in revenue, the company operates on thin margins of roughly 2.7%, meaning small changes in costs or guidance can have an outsized impact on earnings.
That’s why recent EPS declines—from over $24 in 2023 to around $13 in 2025—have translated into increased stock volatility.
What drives price action in UNH isn’t top-line growth—it’s medical cost trends, forward guidance, and regulatory updates, particularly around Medicare Advantage.
As a result, earnings reactions tend to be sharper than you’d expect from a “defensive” healthcare name, with analysts already pricing in ~6% post-earnings moves on average.
For traders, this creates a very specific setup.
UNH becomes most actionable when you see a large earnings-driven move (typically 10% or more) combined with multi-timeframe breaks of structure, aligning with a momentum-based strategy.
Outside of those conditions, the stock tends to be choppy, headline-driven, and less predictable, making it harder to trade cleanly without a clear catalyst.
UNH Stock Statistics 2026 – Frequently Asked Questions (FAQ)
What are the most important UnitedHealth Group stock statistics right now?
The most important unitedhealth group stock statistics include ~$447B in revenue (2025), ~2.7% net margins, and a sharp EPS decline from ~$24 (2023) to ~$13 (2025). These numbers highlight a key shift: strong top-line growth, but weakening profitability.
Why is UnitedHealth’s stock under pressure despite strong revenue growth?
UnitedHealth Group is facing rising medical costs and regulatory pressure, which are compressing margins. Even though revenue continues to grow, profits and earnings are declining, and the market is reacting more to those bottom-line trends than to top-line expansion.
Is UnitedHealth still a good long-term investment?
UNH still has strong fundamentals, including massive scale, diversified revenue streams (insurance + Optum), and solid returns on capital (~17.5% ROE). However, long-term performance will depend on whether the company can stabilize margins and control rising healthcare costs.
Why has UNH earnings per share (EPS) been declining?
EPS has dropped due to a combination of higher medical utilization, Medicare reimbursement pressure, and one-off impacts like cyber-related disruptions and restructuring costs. These factors have reduced profitability even as the business continues to grow.
What is driving volatility in UNH stock?
UNH has become more volatile because it is now highly sensitive to earnings expectations, particularly around:
- Medical cost trends
- Forward guidance
- Regulatory updates
This has led to larger post-earnings price swings (~6% on average).
How does UnitedHealth make money?
UNH operates through two main segments:
- UnitedHealthcare (insurance): The primary revenue driver, especially through Medicare Advantage
- Optum (health services): A growing segment focused on pharmacy, care delivery, and data, with higher long-term margin potential
What are the biggest risks to UnitedHealth stock?
The key risks include:
- Rising medical costs (margin compression)
- Government reimbursement and regulatory pressure
- Political and legal risks (including DOJ scrutiny)
- Declining profitability despite revenue growth
Is UnitedHealth a good stock for trading?
UNH can be a strong event-driven trading opportunity, especially around earnings. It tends to work best when:
- There is a large earnings move (10%+)
- The stock confirms direction with multi-timeframe technical breaks
Outside of those conditions, it often trades choppy and headline-driven.
How does UNH compare to other healthcare insurers?
Many peers like Centene (CNC), Humana (HUM), and Oscar Health (OSCR) are experiencing similar margin pressure from rising healthcare costs and regulatory changes. This suggests the issue is industry-wide, not company-specific.
What should investors watch going forward?
The most important factors to monitor are:
- Medical cost trends and utilization rates
- Medicare Advantage reimbursement changes
- Margin stabilization or further compression
- Performance of the Optum segment
👉 These will ultimately determine whether UNH can return to earnings growth and stock price momentum.
Sources & References
UnitedHealth Group. (2026). UnitedHealth Group reports 2025 results and issues 2026 outlook. Retrieved from https://www.unitedhealthgroup.com/newsroom/2026/2026-01-27-uhg-reports-2025-results-and-issues-2026-outlook.html
Yahoo Finance. (2026). UnitedHealth Group Incorporated (UNH) key statistics. Retrieved from https://finance.yahoo.com/quote/UNH/key-statistics/
Macrotrends. (2026). UnitedHealth Group net income 2010–2026. Retrieved from https://www.macrotrends.net/stocks/charts/UNH/unitedhealth-group/net-income
GuruFocus. (2026). UnitedHealth Group net margin history. Retrieved from https://www.gurufocus.com/term/net-margin/UNH
FullRatio. (2026). UnitedHealth Group earnings per share (EPS) history. Retrieved from https://fullratio.com/stocks/nyse-unh/earnings
Kiplinger. (2026). If you invested $1,000 in UnitedHealth Group, how much would it be worth now? Retrieved from https://www.kiplinger.com/investing/stocks/invested-1000-in-unitedhealth-group-unh-stock-worth-how-much-now
Healthcare Dive. (2026). UnitedHealth earnings impacted by Medicare Advantage costs. Retrieved from https://www.healthcaredive.com/news/unitedhealth-unh-q4-2025-medicare-advantage-troubles/
Investopedia. (2026). How much UnitedHealth stock is expected to move after earnings. Retrieved from https://www.investopedia.com/how-much-unitedhealth-group-stock-is-expected-to-move-after-earnings-unh
MarketWatch. (2026). UnitedHealth faces regulatory and earnings pressure. Retrieved from https://www.marketwatch.com/
Reuters. (2025). Humana earnings highlight rising healthcare costs. Retrieved from https://www.reuters.com/
Becker’s Payer Issues. (2026). Oscar Health posts losses amid rising costs. Retrieved from https://www.beckerspayer.com/
Insurance Business Magazine. (2026). CVS and health insurers face diverging financial outcomes. Retrieved from https://www.insurancebusinessmag.com/
Macrotrends. (2026). UnitedHealth Group dividend yield history. Retrieved from https://www.macrotrends.net/stocks/charts/UNH/unitedhealth-group/dividend-yield-history
Stock Analysis. (2026). UnitedHealth Group dividend data. Retrieved from https://stockanalysis.com/stocks/unh/dividend/
Koyfin. (2026). UnitedHealth Group dividend history and yield. Retrieved from https://www.koyfin.com/company/unh/dividends/
Leave a Reply